VTRS
Price
$10.41
Change
-$0.14 (-1.33%)
Updated
Aug 26 closing price
Capitalization
12.14B
75 days until earnings call
ZTS
Price
$154.79
Change
-$0.40 (-0.26%)
Updated
Aug 26 closing price
Capitalization
68.6B
64 days until earnings call
Interact to see
Advertisement

VTRS vs ZTS

Header iconVTRS vs ZTS Comparison
Open Charts VTRS vs ZTSBanner chart's image
Viatris
Price$10.41
Change-$0.14 (-1.33%)
Volume$9.26M
Capitalization12.14B
ZOETIS
Price$154.79
Change-$0.40 (-0.26%)
Volume$3.61M
Capitalization68.6B
VTRS vs ZTS Comparison Chart in %
Loading...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
VTRS vs. ZTS commentary
Aug 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VTRS is a Buy and ZTS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 27, 2025
Stock price -- (VTRS: $10.41 vs. ZTS: $154.79)
Brand notoriety: VTRS: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: VTRS: 105% vs. ZTS: 111%
Market capitalization -- VTRS: $12.14B vs. ZTS: $68.6B
VTRS [@Pharmaceuticals: Generic] is valued at $12.14B. ZTS’s [@Pharmaceuticals: Generic] market capitalization is $68.6B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

VTRS’s FA Score shows that 2 FA rating(s) are green whileZTS’s FA Score has 1 green FA rating(s).

  • VTRS’s FA Score: 2 green, 3 red.
  • ZTS’s FA Score: 1 green, 4 red.
According to our system of comparison, VTRS is a better buy in the long-term than ZTS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

VTRS’s TA Score shows that 5 TA indicator(s) are bullish while ZTS’s TA Score has 7 bullish TA indicator(s).

  • VTRS’s TA Score: 5 bullish, 4 bearish.
  • ZTS’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, ZTS is a better buy in the short-term than VTRS.

Price Growth

VTRS (@Pharmaceuticals: Generic) experienced а -1.42% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was -0.57% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.88%. For the same industry, the average monthly price growth was +10.13%, and the average quarterly price growth was +74.80%.

Reported Earning Dates

VTRS is expected to report earnings on Nov 10, 2025.

ZTS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.88% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($68.6B) has a higher market cap than VTRS($12.1B). VTRS has higher P/E ratio than ZTS: VTRS (236.20) vs ZTS (26.64). ZTS YTD gains are higher at: -4.068 vs. VTRS (-13.145). ZTS has higher annual earnings (EBITDA): 4.02B vs. VTRS (-493.3M). ZTS has more cash in the bank: 1.44B vs. VTRS (406M). ZTS has less debt than VTRS: ZTS (6.79B) vs VTRS (14.5B). VTRS has higher revenues than ZTS: VTRS (14.1B) vs ZTS (9.39B).
VTRSZTSVTRS / ZTS
Capitalization12.1B68.6B18%
EBITDA-493.3M4.02B-12%
Gain YTD-13.145-4.068323%
P/E Ratio236.2026.64887%
Revenue14.1B9.39B150%
Total Cash406M1.44B28%
Total Debt14.5B6.79B214%
FUNDAMENTALS RATINGS
VTRS vs ZTS: Fundamental Ratings
VTRS
ZTS
OUTLOOK RATING
1..100
2419
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
35
Fair valued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
9519
PRICE GROWTH RATING
1..100
4559
P/E GROWTH RATING
1..100
182
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (12) in the null industry is in the same range as ZTS (35) in the Pharmaceuticals Generic industry. This means that VTRS’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's Profit vs Risk Rating (88) in the Pharmaceuticals Generic industry is in the same range as VTRS (100) in the null industry. This means that ZTS’s stock grew similarly to VTRS’s over the last 12 months.

ZTS's SMR Rating (19) in the Pharmaceuticals Generic industry is significantly better than the same rating for VTRS (95) in the null industry. This means that ZTS’s stock grew significantly faster than VTRS’s over the last 12 months.

VTRS's Price Growth Rating (45) in the null industry is in the same range as ZTS (59) in the Pharmaceuticals Generic industry. This means that VTRS’s stock grew similarly to ZTS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is significantly better than the same rating for ZTS (82) in the Pharmaceuticals Generic industry. This means that VTRS’s stock grew significantly faster than ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
VTRSZTS
RSI
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 3 days ago
68%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
54%
Bearish Trend 3 days ago
63%
Momentum
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 3 days ago
63%
MACD
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 3 days ago
54%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 3 days ago
59%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 3 days ago
57%
Advances
ODDS (%)
Bullish Trend 6 days ago
67%
Bullish Trend 8 days ago
56%
Declines
ODDS (%)
Bearish Trend 28 days ago
66%
Bearish Trend 28 days ago
56%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
64%
Bullish Trend 3 days ago
59%
Aroon
ODDS (%)
Bullish Trend 3 days ago
51%
Bearish Trend 3 days ago
59%
View a ticker or compare two or three
Interact to see
Advertisement
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FBT171.910.80
+0.47%
First Trust NYSE Arca Biotech ETF
IMTB43.780.08
+0.18%
iShares Core 5-10 Year USD Bond ETF
EMTY11.47N/A
-0.02%
ProShares Decline of the Retl Store ETF
IYRI50.41-0.16
-0.32%
NEOS Real Estate High Income ETF
PSCE40.69-0.28
-0.69%
Invesco S&P SmallCap Energy ETF

ZTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
-0.26%
ELAN - ZTS
45%
Loosely correlated
+0.62%
VTRS - ZTS
44%
Loosely correlated
-1.33%
PAHC - ZTS
43%
Loosely correlated
+2.19%
HLN - ZTS
38%
Loosely correlated
-0.52%
AMRX - ZTS
37%
Loosely correlated
+1.08%
More